UNBS5162, a Novel Naphthalimide That Decreases CXCL Chemokine Expression in Experimental Prostate Cancers

UNBS5162, a Novel Naphthalimide That Decreases CXCL Chemokine Expression in Experimental Prostate Cancers

Several naphthalimides have been evaluated clinically as potential anticancer agents. UNBS3157, a naphthalimide that belongs to the same class as amonafide, was designed to avoid the specific activating metabolism that induces amonafide’s hematotoxicity. The current study shows that UNBS3157 rapidl...

Full description

Bibliographic Details
Main Authors: Tatjana Mijatovic, Tina Mahieu, Céline Bruyère, Nancy De Nève, Janique Dewelle, Gentiane Simon, Mischaël J.M. Dehoux, Ellen van der Aar, Benjamin Haibe-Kains, Gianluca Bontempi, Christine Decaestecker, Eric Van Quaquebeke, Francis Darro, Robert Kiss
Format: Article
Language:English
Published: Elsevier 2008-06-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558608801467

Internet

http://www.sciencedirect.com/science/article/pii/S1476558608801467

Similar Items